| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 09/15/2011 | WO2011022371A3 Gel product |
| 09/15/2011 | WO2011012369A3 Coating agent for the dip coating of capsule halves |
| 09/15/2011 | WO2011009436A3 Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically |
| 09/15/2011 | WO2010146407A9 Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
| 09/15/2011 | WO2010135396A3 Formulations of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione |
| 09/15/2011 | WO2010120662A3 Bioavailable compositions of amorphous alpha-(n-sulfonamido)acetamide compound |
| 09/15/2011 | WO2010065751A3 Formulations of guanylate cyclase c agonists and methods of use |
| 09/15/2011 | WO2010048275A3 Lyophilized recombinant vwf formulations |
| 09/15/2011 | WO2008054874A3 Particles with high uniform loading of nanoparticles and methods of preparation thereof |
| 09/15/2011 | US20110225660 Orally administrable immunostimulant product for aquaculture |
| 09/15/2011 | US20110224723 Cyanoacrylate tissue adhesives |
| 09/15/2011 | US20110224282 iRNA Agents Targeting VEGF |
| 09/15/2011 | US20110224246 Pharmaceutical compositions comprising ascomycin |
| 09/15/2011 | US20110223257 Releasable fusogenic lipids for nucleic acids delivery systems |
| 09/15/2011 | US20110223256 Method For Stabilizing Flavonoid Aqueous Dispersion |
| 09/15/2011 | US20110223255 Implantable products comprising nanoparticles |
| 09/15/2011 | US20110223254 Functionalized diphenolics and absorbable polymers therefrom |
| 09/15/2011 | US20110223253 Physically stabilized biodegradable osteochondral implant and methods for its manufacture and implantation |
| 09/15/2011 | US20110223252 Electrolyte purgative |
| 09/15/2011 | US20110223251 Bacterial composition |
| 09/15/2011 | US20110223250 Multi-vitamin and mineral nutritional supplements |
| 09/15/2011 | US20110223249 Extended release compositions comprising mycophenolate sodium and processes thereof |
| 09/15/2011 | US20110223248 Methods and compositions for treating lactose intolerance |
| 09/15/2011 | US20110223247 Pharmaceutical compositions for release control of methylphenidate |
| 09/15/2011 | US20110223246 Docosahexaenoic acid bound in phospholipids and method of recovering same from a natural source |
| 09/15/2011 | US20110223245 Controlled-release formulations of pramipexole |
| 09/15/2011 | US20110223244 Alcohol resistant enteric pharmaceutical compositions |
| 09/15/2011 | US20110223243 Artificial oxygen carriers and use thereof |
| 09/15/2011 | US20110223242 Nanoparticles containing a peptide, vectors containing said nanoparticles, and pharmaceutical uses of said nanoparticles and vectors |
| 09/15/2011 | US20110223241 Combination methods and compositions |
| 09/15/2011 | US20110223240 Compounds for reversing and inhibiting protein aggregation, and methods for making and using them |
| 09/15/2011 | US20110223239 Spermicidal and virucidal properties of various forms of sophorolipids |
| 09/15/2011 | US20110223238 Bisbenzamidines for the Treatment of Pneumonia |
| 09/15/2011 | US20110223237 Selegiline-containing adhesive preparation |
| 09/15/2011 | US20110223236 Selegiline-containing adhesive preparation |
| 09/15/2011 | US20110223235 Selegiline-containing adhesive preparation |
| 09/15/2011 | US20110223234 Process for Manufacturing Chewable Dosage Forms for Drug Delivery and Products Thereof |
| 09/15/2011 | US20110223233 Microfabricated nanopore device for sustained release of therapeutic agent |
| 09/15/2011 | US20110223230 Hydrogel formulations |
| 09/15/2011 | US20110223229 Immobilised biological entities |
| 09/15/2011 | US20110223226 Shelf stable capsules |
| 09/15/2011 | US20110223225 Solid oil powders |
| 09/15/2011 | US20110223221 Stabilization processes of cation radicals of phenothiazinic compounds, cosmeceutical formulations and methods for skin diseases and disturbances prevention |
| 09/15/2011 | US20110223217 Block copolymers and uses thereof |
| 09/15/2011 | US20110223216 Nanoparticles and Porous Particles and Methods of Making the Same |
| 09/15/2011 | US20110223215 Process for making a topical scrub |
| 09/15/2011 | US20110223214 Use of carboxymethylcellulose to control ejectability and solidification time of compositions comprising one or more bioresorbable ceramics |
| 09/15/2011 | US20110223213 Highly pure ranolazine or a pharmaceutically acceptable salt thereof |
| 09/15/2011 | US20110223212 Drug eluting superhydrophobic coatings |
| 09/15/2011 | US20110223211 Pharmaceutical formulations containing irbesartan |
| 09/15/2011 | US20110223210 HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| 09/15/2011 | US20110223209 Oxygen delivering scaffold for tissue engineering |
| 09/15/2011 | US20110223208 Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations |
| 09/15/2011 | US20110223207 Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same |
| 09/15/2011 | US20110223206 Micelle compositions and process for the preparation thereof |
| 09/15/2011 | US20110223205 Treatment of amyotrophic lateral sclerosis using umbilical derived cells |
| 09/15/2011 | US20110223204 Treatment of pain with gap junction modulation compounds |
| 09/15/2011 | US20110223203 Nanocluster compositions and methods |
| 09/15/2011 | US20110223202 Cationic core-shell peptide nonoparticles |
| 09/15/2011 | US20110223201 Immunonanotherapeutics Providing a Th1-Biased Response |
| 09/15/2011 | US20110223116 Apparatus and method for aerosol delivery to the lungs or other locations of the body |
| 09/15/2011 | US20110223115 Sublingual buccal effervescent |
| 09/15/2011 | US20110223113 Propellant for dosing aerosols comprising packagings |
| 09/15/2011 | US20110223111 Calcium carbonate microstructures useful in encapsulation applications and a process for the preparation thereof |
| 09/15/2011 | US20110220265 Preparation for External Use |
| 09/15/2011 | DE102009052972A1 Verfahren zur Verhinderung der Kristallisation von Arzneistoffen in einem Polymerfilm A method for preventing crystallization of drugs in a polymer film |
| 09/15/2011 | CA2828086A1 Foamable formulation |
| 09/15/2011 | CA2800235A1 Rifaximin ready-to-use suspension |
| 09/15/2011 | CA2793846A1 Triggered cargo release from nanoparticle stabilized liposomes |
| 09/15/2011 | CA2792862A1 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 09/15/2011 | CA2792771A1 Injectable drug delivery system |
| 09/15/2011 | CA2792754A1 .beta.-mannosylceramide and stimulation of nkt cell anti-tumor immunity |
| 09/15/2011 | CA2792679A1 A novel mucosal vaccination approach for herpes simplex virus type-2 |
| 09/15/2011 | CA2792647A1 Compositions for colon lavage and methods of making and using same |
| 09/15/2011 | CA2792601A1 Solid compositions of amorphous hcv inhibitors |
| 09/15/2011 | CA2792523A1 Alcohol resistant enteric pharmaceutical compositions |
| 09/15/2011 | CA2792520A1 Synthesis of alpha-tocopherolquinone derivatives, and methods of using the same |
| 09/15/2011 | CA2792392A1 The use of amisulpride as an anti-emetic |
| 09/15/2011 | CA2792273A1 Dabigatran etexilate-containing pharmaceutical composition |
| 09/15/2011 | CA2792232A1 A device for the manufacture of a dosage form with a hole and method of manufacture |
| 09/15/2011 | CA2791988A1 A novel method for delivery and use of isothiocyanates for prophylaxis and/or therapy of bladder cancer |
| 09/15/2011 | CA2791693A1 Intravenous formulations of coenzyme q10 (coq10) and methods of use thereof |
| 09/15/2011 | CA2791559A1 Micelle compositions and process for the preparation thereof |
| 09/15/2011 | CA2791498A1 Ketoprofen-containing water-based patch |
| 09/15/2011 | CA2790407A1 Ophthalmic formulations |
| 09/14/2011 | EP2365077A1 iRNA agents targeting VEGF |
| 09/14/2011 | EP2365007A2 Magnetically controllable drug and gene delivery stents |
| 09/14/2011 | EP2364733A2 Selegiline-Containing Adhesive Preparation |
| 09/14/2011 | EP2364713A1 Dermatological composition for use in the treatment of skin burns, skin diseases and infected wounds |
| 09/14/2011 | EP2364709A1 Antimicrobial compositions and methods of use |
| 09/14/2011 | EP2364696A1 Formulations for delivery via pressurised metered dose inhalers |
| 09/14/2011 | EP2364695A1 Methylphenidate patch preparation |
| 09/14/2011 | EP2364694A1 Controlled-release formulations of pramipexole |
| 09/14/2011 | EP2364693A2 Anhydrous multiphase gel system |
| 09/14/2011 | EP2364692A2 Compositions including at least one derivative of naphtoic acid, benzoyl peroxide and at least one film-forming agent, methods for preparing same and uses thereof |
| 09/14/2011 | EP2364691A1 VEGF antagonist formulations suitable for intravitreal administration |
| 09/14/2011 | EP2364690A1 Orally administrable pharmaceutical pellet of epidermal growth factor |
| 09/14/2011 | EP2364680A1 Microimplants for ocular administration |
| 09/14/2011 | EP2364600A1 Liquid-filled chitosan-anionic liposoluble capsule dispsersions |
| 09/14/2011 | EP2364317A2 Dopamine receptor ligands with enhanced duration of action |